Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphocytic leukemia.

Leslie Andritsos1, Hanna Khoury

  • 1Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University, 660 South Euclid Avenue, Campus Box 8056, St. Louis, MO 63110, USA. andritsosl@earthlink.net

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary

New therapies offer improved responses for chronic lymphocytic leukemia (CLL) but not survival benefits. Allogeneic stem cell transplantation offers a potential cure for select CLL patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Rare Case of Acute Aleukemic Mast Cell Leukemia With Osteoblastic Lesions in the Appendicular Skeleton.

Journal of hematology·2025
Same author

Hairy cell leukemia variant and WHO classification correspondence Re: 5<sup>th</sup> edition WHO classification haematolymphoid tumors: lymphoid neoplasms.

Leukemia·2024
Same author

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.

Blood cancer journal·2022
Same author

Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States.

Journal of managed care & specialty pharmacy·2022
Same author

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.

Leukemia·2021
Same author

A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia·2021

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Chronic lymphocytic leukemia (CLL) treatment has evolved from palliative care to targeted therapies.
  • Recent decades have seen the emergence of novel agents and treatment strategies for CLL.
  • Fludarabine demonstrated high response rates in CLL, but survival benefits remain elusive.

Purpose of the Study:

  • To review the advancements in chronic lymphocytic leukemia (CLL) treatment.
  • To evaluate the efficacy of emerging therapies including purine analogs, stem cell transplantation, and monoclonal antibodies.
  • To discuss the potential for cure and expanded treatment options in CLL.

Main Methods:

  • Review of fludarabine's efficacy against chlorambucil-resistant CLL.
  • Analysis of allogeneic hematopoietic stem cell transplantation (HSCT) for CLL cure.
  • Assessment of monoclonal antibodies like rituximab and alemtuzumab in CLL treatment.
  • Exploration of novel HSCT methods and combination therapies.

Main Results:

  • Fludarabine shows high response rates but no survival benefit in CLL.
  • Allogeneic HSCT offers a potential cure but is limited to select patients.
  • Monoclonal antibodies demonstrate activity in both untreated and resistant CLL.
  • Novel transplantation techniques and combination therapies are under investigation.

Conclusions:

  • Chlorambucil may remain a preferred first-line therapy for CLL when indicated.
  • Allogeneic HSCT, particularly with novel approaches, holds promise for CLL cure.
  • Combination therapies involving monoclonal antibodies and chemotherapy are a focus for future CLL treatment.

Related Experiment Videos